Asenapine vs Paliperidone (Invega)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Asenapine
Marketed by AbbVie and partners
NCT00212784 · Phase 3 · completed
This 52-week trial randomly assigned 1,225 people with schizophrenia to asenapine or to olanzapine, with participants, carers, investigators and outcome assessors all unaware of assignment. The primary measure was change in total PANSS symptom score. Asenapine improved symptoms by 21.0 points against 27.5 points for olanzapine, a difference favouring olanzapine at p<0.0001, so asenapine was less effective than its active comparator on this measure.
Reported efficacy
Change in total PANSS score at endpoint (Screening, Week 76, 100, and once every 24 weeks thereafter until endpoint): Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint (unclear)
Result source: NCT00212771
Paliperidone (Invega)
Marketed by Johnson & Johnson
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
Reported efficacy
Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)
Result source: NCT04072575
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Asenapine | Paliperidone (Invega) |
|---|---|---|
| PANSS total, change | -25.5 vs -17.8−7.7 vs placeboNCT0119025418 other results
| -9.8 vs -7.9−1.9 vs placeboNCT005183238 other results
|
| CGI-S, change | -1.3 vs -0.8−0.5 vs placeboNCT0119025417 other results
| 0 vs 0±0 vs placeboNCT005183237 other results
|
| PANSS response | 39.3% vs 20.7%+18.6 vs placeboNCT010981101 other result
| 76.8% vs 81.6%vs AripiprazoleNCT010090471 other result
|
| PSP, change | —Not posted · NCT00212771 | 17.1 vs 17.1vs AripiprazoleNCT010090473 other results
|
| Relapse (% of patients) | —Not posted · NCT00212771 | —Not posted · NCT03485417 |
PANSS total, change
- Asenapine
- -25.5 vs -17.8−7.7 vs placeboNCT01190254
18 other results
- -21.7 vs -16.2 NCT01617187
- -12.2 vs -0.9 NCT01098110
- -14.2 vs -0.9 NCT01098110
- -23.7 vs -17.8 NCT01190254
- -17.4 vs -16.2 NCT01617187
- -19 vs -15.4 NCT01617187
- -17.1 vs -15.5 NCT01617187
- -14.8 vs -13.2 NCT01617187
- -12.5 vs -10.7 NCT01617187
- -9.1 vs -7.1 NCT01617187
- -4.9 vs -4.8 NCT01617187
- -17 vs -15.4 NCT01617187
- -12.3 vs -15.5 NCT01617187
- -12 vs -13.2 NCT01617187
- -9.9 vs -10.7 NCT01617187
- -7.2 vs -7.1 NCT01617187
- -4 vs -4.8 NCT01617187
- -21 vs -27.5 NCT00212784
- Paliperidone (Invega)
- -9.8 vs -7.9−1.9 vs placeboNCT00518323
8 other results
- -17.3 vs -7.9 NCT00518323
- -13.8 vs -7.9 NCT00518323
- -9.1 vs 3.8 NCT00396565
- -19.3 vs -19.8 NCT01009047
- -13.5 vs -16.6 NCT00645099
- -25.6 vs -26.8 NCT01009047
- -15 vs -11.7 NCT00524043
- -8.9 vs -11.7 NCT00524043
CGI-S, change
- Asenapine
- -1.3 vs -0.8−0.5 vs placeboNCT01190254
17 other results
- -1.2 vs -1 NCT01617187
- -0.7 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.8 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.2 vs -0.2 NCT01617187
- -0.8 vs -0.2 NCT01098110
- -1.1 vs -0.8 NCT01190254
- -0.9 vs -1 NCT01617187
- -0.9 vs -0.8 NCT01617187
- -0.7 vs -0.8 NCT01617187
- -0.6 vs -0.7 NCT01617187
- -0.6 vs -0.5 NCT01617187
- -0.3 vs -0.3 NCT01617187
- -0.1 vs -0.2 NCT01617187
- Paliperidone (Invega)
- 0 vs 0±0 vs placeboNCT00518323
7 other results
- -1 vs 0 NCT00518323
- -1 vs 0 NCT00518323
- -0.4 vs 0.2 NCT00396565
- -1 vs -1 NCT01009047
- -1 vs -1 NCT01009047
- -0.5 vs -1 NCT00524043
- 0 vs -1 NCT00524043
PANSS response
- Asenapine
- 39.3% vs 20.7%+18.6 vs placeboNCT01098110
1 other result
- 43.8% vs 20.7% NCT01098110
- Paliperidone (Invega)
- 76.8% vs 81.6%vs AripiprazoleNCT01009047
1 other result
- 67.9% vs 76.3% NCT01009047
PSP, change
- Asenapine
- —Not posted · NCT00212771
- Paliperidone (Invega)
- 17.1 vs 17.1vs AripiprazoleNCT01009047
3 other results
- 12.2 vs 12.2 NCT01009047
- 5.7 vs 1.6 NCT00524043
- 2.9 vs 1.6 NCT00524043
Relapse (% of patients)
- Asenapine
- —Not posted · NCT00212771
- Paliperidone (Invega)
- —Not posted · NCT03485417
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
8 other shared endpoints and safety
Coverage. Asenapine: 12 of 12 rows · Paliperidone (Invega): 12 of 12 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Asenapine Rows use multiple source trials | Paliperidone (Invega) Rows use multiple source trials |
|---|---|---|
| CGAS absolute change · score | 15 vs 10.2 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose12.8 vs 10.2 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | 8.6 vs 5 placebo score @ 6wka,b,c,d NCT00518323 · Phase 3 · registry result, not featured evidence show 2 more doses4.4 vs 5 placebo score @ 6wk NCT00518323 · Phase 3 · registry result, not featured evidence 13.1 vs 5 placebo score @ 6wk NCT00518323 · Phase 3 · registry result, not featured evidence |
| PANSS 30% responder rate · % of participants | 25.2% (n=111) vs 19.2% (n=99) placebo @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose14.6% (n=96) vs 19.2% (n=99) placebo @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | 25.4% (n=134) vs 9.4% (n=138) placebo @ 6wkb,c NCT00396565 · Phase 3 · registry result, not featured evidence |
| PANSS General Psychopathology absolute change · score | -10.1 vs -8 placebo score @ 6wk5 mg BIDa,b,c NCT01617187 · Phase 3 · registry result, not featured evidence show 1 more dose-8.9 vs -8 placebo score @ 6wk2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence | -4.1 vs 2.2 placebo score @ 6wkb,c NCT00396565 · Phase 3 · registry result, not featured evidence |
| PANSS Marder Negative absolute change · score | -5.3 vs -3.7 placebo score @ 8wk5.0 mg BIDa,b,c NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-5.2 vs -3.7 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -4.3 vs -4.7 Aripiprazole score @ 8wkb,c NCT01009047 · Phase 3 · registry result, not featured evidence |
| PANSS Negative Subscale absolute change · score | -4.9 vs -3.4 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-4.8 vs -3.4 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -2.4 vs 0 placebo score @ 6wkb,c,d NCT00396565 · Phase 3 · registry result, not featured evidence |
| PANSS Positive Subscale absolute change · score | -9.1 vs -6 placebo score @ 8wk5.0 mg BIDa,b,c,d NCT01190254 · Phase 3 · registry result, not featured evidence show 1 more dose-7.9 vs -6 placebo score @ 8wk2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence | -2.6 vs 1.6 placebo score @ 6wkb,c,d NCT00396565 · Phase 3 · registry result, not featured evidence |
| PANSS Total absolute change · score No placebo or comparator arm | -11.08 score @ 52wka,b,c NCT01244828 · Phase 3 · registry result, not featured evidence show 1 more dose-5.48 score NCT01244828 · Phase 3 · registry result, not featured evidence | -12.6 score @ 104wka,b,c NCT00488319 · Phase 3 · registry result, not featured evidence show 2 more doses-22.4 score @ 104wk NCT00488319 · Phase 3 · registry result, not featured evidence -18.9 score @ 104wk NCT00488319 · Phase 3 · registry result, not featured evidence |
| Weight absolute change · kg | 0 vs 2.6 Olanzapine kg @ 26wkb,c,e NCT00145496 · Phase 3 · registry result, not featured evidence | 1.16 vs 3.81 Olanzapine kg @ 24wkb,c,e NCT00645099 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 44.4%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results16.7%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 54.8%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 1%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 49.7% NCT01244828 · Phase 3 · registry result, not featured evidence 35.2%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 40.1%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 50%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.9%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 20.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 17.3%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 33.7% NCT00174265 · Phase 3 · registry result, not featured evidence 50.4% NCT00145496 · Phase 3 · registry result, not featured evidence 30.4% NCT00150176 · Phase 3 · registry result, not featured evidence 15.7% NCT00265343 · Phase 3 · registry result, not featured evidence 67.7% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence 33.3%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 25%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 41.2%f NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results48.4% NCT00761579 · Phase 4 · registry result, not featured evidence 36.4% NCT00761605 · Phase 4 · registry result, not featured evidence 20% NCT01387542 · Phase 4 · registry result, not featured evidence 11.3% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 32.6% NCT01724359 · Phase 4 · registry result, not featured evidence 27.1% NCT01577186 · Phase 4 · registry result, not featured evidence 40.5% NCT00757705 · Phase 4 · registry result, not featured evidence 27.8% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 25.4%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 40%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 47%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 0%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 0%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 36.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 50.2%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 38.5%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 24.8% NCT01009047 · Phase 3 · registry result, not featured evidence 19.1% NCT01541371 · Phase 3 · registry result, not featured evidence 50% NCT00473434 · Phase 3 · registry result, not featured evidence 20.4% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 28.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 29.8%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 22.9%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 35.2%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 16.7%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 15.4% NCT01606228 · Phase 3 · registry result, not featured evidence 45.4% NCT01561898 · Phase 3 · registry result, not featured evidence 35.3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 22.2%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 22.3%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 0%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 0%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 23.6% NCT01244828 · Phase 3 · registry result, not featured evidence 17%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 17.6%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 0%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 5.1%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 7.5%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 6.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 8.1% NCT00174265 · Phase 3 · registry result, not featured evidence 17.2% NCT00145496 · Phase 3 · registry result, not featured evidence 8.2% NCT00150176 · Phase 3 · registry result, not featured evidence 7.5% NCT00265343 · Phase 3 · registry result, not featured evidence 11.8% NCT00156065 · Phase 3 · registry result, not featured evidence —5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 4.8%f NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results5.3% NCT00761579 · Phase 4 · registry result, not featured evidence 6.7% NCT00761605 · Phase 4 · registry result, not featured evidence 7.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence —Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 10.5% NCT01724359 · Phase 4 · registry result, not featured evidence 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence 6.4% NCT00757705 · Phase 4 · registry result, not featured evidence 2.5% NCT01577160 · Phase 4 · registry result, not featured evidence —Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence 2.6%Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence —TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 2.9%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence —PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence —Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence —Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 1.7%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 9.5%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 2.6%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 4.4% NCT01009047 · Phase 3 · registry result, not featured evidence 3.7% NCT01541371 · Phase 3 · registry result, not featured evidence 4.7% NCT00473434 · Phase 3 · registry result, not featured evidence 3.1% NCT00566631 · Phase 3 · registry result, not featured evidence — NCT00645099 · Phase 3 · registry result, not featured evidence 8.3%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 6.2%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 1.9%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 0.5% NCT01606228 · Phase 3 · registry result, not featured evidence 14.4% NCT01561898 · Phase 3 · registry result, not featured evidence 3.7% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 0%5 mg twice dailyf NCT01549041 · Phase 4 · registry result, not featured evidence show 23 more results0%10 mg daily in the evening NCT01549041 · Phase 4 · registry result, not featured evidence 20.4%5/10 mg BID NCT01142596 · Phase 3 · registry result, not featured evidence 4.4%5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 5.2%2.5 mg BID NCT01617187 · Phase 3 · registry result, not featured evidence 8.9% NCT01244828 · Phase 3 · registry result, not featured evidence 5.7%5 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 2.8%10 mg BID NCT01098110 · Phase 3 · registry result, not featured evidence 12.5%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 3.6%Asenapine - Participants Who Were NCT01190267 · Phase 3 · registry result, not featured evidence 2.8%5.0 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 3.1%2.5 mg BID NCT01190254 · Phase 3 · registry result, not featured evidence 4.7% NCT00174265 · Phase 3 · registry result, not featured evidence 12.3% NCT00145496 · Phase 3 · registry result, not featured evidence 3.1% NCT00150176 · Phase 3 · registry result, not featured evidence 6.7% NCT00265343 · Phase 3 · registry result, not featured evidence 14.1% NCT00156065 · Phase 3 · registry result, not featured evidence 0%5 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence —10 mg NCT01206517 · Phase 1 · registry result, not featured evidence 0%2.5 mg NCT01206517 · Phase 1 · registry result, not featured evidence | 7.3%f NCT00784238 · Phase 4 · registry result, not featured evidence show 35 more results12.1% NCT00761579 · Phase 4 · registry result, not featured evidence 9.8% NCT00761605 · Phase 4 · registry result, not featured evidence 2.5% NCT01387542 · Phase 4 · registry result, not featured evidence 0.8% NCT01362439 · Phase 4 · registry result, not featured evidence 1.9%Paliperidone ER - Extension Phase NCT01010776 · Phase 4 · registry result, not featured evidence 6.5%Paliperidone ER - Main Phase NCT01010776 · Phase 4 · registry result, not featured evidence 7.4% NCT01724359 · Phase 4 · registry result, not featured evidence 7.7% NCT01577186 · Phase 4 · registry result, not featured evidence 3.7% NCT00757705 · Phase 4 · registry result, not featured evidence 0% NCT01577160 · Phase 4 · registry result, not featured evidence 2.4%Paliperidone ER Phase NCT00535145 · Phase 4 · registry result, not featured evidence —Study Treatment NCT00535145 · Phase 4 · registry result, not featured evidence 0%TAU - Pali ER NCT00535145 · Phase 4 · registry result, not featured evidence 7.1%6 mg NCT00524043 · Phase 4 · registry result, not featured evidence 10.6%1.5 mg NCT00524043 · Phase 4 · registry result, not featured evidence 4%PALI ER Delayed Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 3.1%PALI ER Immediate Initiation NCT00535132 · Phase 4 · registry result, not featured evidence 4.3%Paliperidone DB/Paliperidone Open- NCT01662310 · Phase 3 · registry result, not featured evidence 3.1%Paliperidone: Double Blind (DB) Ph NCT01662310 · Phase 3 · registry result, not featured evidence 3.4%Paliperidone (Double-blind)/Palipe NCT00488319 · Phase 3 · registry result, not featured evidence 18.9%Paliperidone (No Double-blind)/Pal NCT00488319 · Phase 3 · registry result, not featured evidence 23.1%Placebo/Paliperidone NCT00488319 · Phase 3 · registry result, not featured evidence 6.2% NCT01009047 · Phase 3 · registry result, not featured evidence 0.2% NCT01541371 · Phase 3 · registry result, not featured evidence 42.2% NCT00473434 · Phase 3 · registry result, not featured evidence 7.8% NCT00566631 · Phase 3 · registry result, not featured evidence 8.8% NCT00645099 · Phase 3 · registry result, not featured evidence 6.8%Paliperidone ER: Lack of Efficacy NCT01662648 · Phase 3 · registry result, not featured evidence 4.9%Paliperidone ER: Lack of Tolerabil NCT01662648 · Phase 3 · registry result, not featured evidence 2.1%Pali ER High NCT00518323 · Phase 3 · registry result, not featured evidence 3.7%Pali ER Low NCT00518323 · Phase 3 · registry result, not featured evidence 2.1%Pali ER Medium NCT00518323 · Phase 3 · registry result, not featured evidence 2.1% NCT01606228 · Phase 3 · registry result, not featured evidence — NCT01561898 · Phase 3 · registry result, not featured evidence 3% NCT00396565 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 5 mg twice dailyf daytime drowsiness 22.2% NCT01549041 · Phase 4 · registry result, not featured evidence show 19 more results10 mg daily in the evening daytime drowsiness 0% NCT01549041 · Phase 4 · registry result, not featured evidence 5/10 mg BID nasopharyngitis 21.7% schizophrenia 10.8% somnolence 10.8% NCT01142596 · Phase 3 · registry result, not featured evidence 5 mg BID insomnia 15% (placebo 13.9%) headache 8.8% (placebo 2%) anxiety 7.1% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence 2.5 mg BID headache 10.3% (placebo 2%) insomnia 9.3% (placebo 13.9%) anxiety 7.2% (placebo 11.9%) NCT01617187 · Phase 3 · registry result, not featured evidence nasopharyngitis 21% somnolence 12.7% weight increased 12.7% NCT01244828 · Phase 3 · registry result, not featured evidence 5 mg BID akathisia 11.4% (placebo 5.2%) hypoaesthesia oral 10.9% (placebo 3.4%) insomnia 9.7% (placebo 12.1%) NCT01098110 · Phase 3 · registry result, not featured evidence 10 mg BID schizophrenia 13.8% (placebo 24.1%) somnolence 12.2% (placebo 1.7%) akathisia 10.5% (placebo 5.2%) NCT01098110 · Phase 3 · registry result, not featured evidence accidental overdose 12.5% acne 12.5% akathisia 12.5% NCT01190267 · Phase 3 · registry result, not featured evidence somnolence 14.8% headache 6.6% sedation 5.1% NCT01190267 · Phase 3 · registry result, not featured evidence 5.0 mg BID somnolence 17% (placebo 6.9%) sedation 11.3% (placebo 2%) insomnia 9.4% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence 2.5 mg BID somnolence 20.4% (placebo 6.9%) dizziness 7.1% (placebo 1%) headache 7.1% (placebo 5.9%) NCT01190254 · Phase 3 · registry result, not featured evidence insomnia 10.6% weight increased 5.9% headache 2.4% NCT00174265 · Phase 3 · registry result, not featured evidence insomnia 17.6% somnolence 14.8% headache 13.5% NCT00145496 · Phase 3 · registry result, not featured evidence insomnia 20.1% (placebo 24.5%) somnolence 16% (placebo 17.2%) weight increased 14.4% (placebo 10.9%) NCT00150176 · Phase 3 · registry result, not featured evidence headache 5.2% influenza 5.2% schizophrenia 5.2% NCT00265343 · Phase 3 · registry result, not featured evidence insomnia 18.5% headache 10.9% parkinsonism 10.9% NCT00156065 · Phase 3 · registry result, not featured evidence 5 mg dystonia 66.7% dizziness 33.3% nausea 33.3% NCT01206517 · Phase 1 · registry result, not featured evidence 10 mg hypoaesthesia oral 50% dizziness 38.9% dysgeusia 38.9% NCT01206517 · Phase 1 · registry result, not featured evidence 2.5 mg sedation 33.3% dysgeusia 16.7% hypoaesthesia oral 16.7% NCT01206517 · Phase 1 · registry result, not featured evidence | f akathisia 8.3% extrapyramidal disorder 4.8% insomnia 4.8% NCT00784238 · Phase 4 · registry result, not featured evidence show 33 more resultsakathisia 18.4% weight increased 15.3% muscle rigidity 7.4% NCT00761579 · Phase 4 · registry result, not featured evidence insomnia 12.4% akathisia 11.4% weight increased 9.3% NCT00761605 · Phase 4 · registry result, not featured evidence drowsiness 15% headache 15% insomnia 12.5% NCT01387542 · Phase 4 · registry result, not featured evidence insomnia 3% weight increase 3% extrapyramidal symptoms 2.3% NCT01362439 · Phase 4 · registry result, not featured evidence weight increased 12.6% insomnia 8.8% depression 4.4% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 14.9% anxiety 10.7% weight increased 10.7% NCT01010776 · Phase 4 · registry result, not featured evidence insomnia 25.3% akathisia 23.2% parkinsonism 15.8% NCT01724359 · Phase 4 · registry result, not featured evidence extrapyramidal disorder 11.7% upper respiratory tract infection 6.7% tremor 4.8% NCT01577186 · Phase 4 · registry result, not featured evidence insomnia 20.7% extrapyramidal disorder 13.7% anxiety 11.7% NCT00757705 · Phase 4 · registry result, not featured evidence insomnia 15.9% constipation 11.3% extrapyramidal disorder 9.6% NCT01577160 · Phase 4 · registry result, not featured evidence weight increased 6% headache 3.6% akathisia 2.4% NCT00535145 · Phase 4 · registry result, not featured evidence 6 mg headache 11.4% (placebo 15.6%) insomnia 10% (placebo 9.4%) tremor 10% (placebo 3.1%) NCT00524043 · Phase 4 · registry result, not featured evidence 1.5 mg insomnia 13.6% (placebo 9.4%) dizziness 7.6% (placebo 1.6%) headache 7.6% (placebo 15.6%) NCT00524043 · Phase 4 · registry result, not featured evidence constipation 9.1% insomnia 9.1% somnolence 8.1% NCT00535132 · Phase 4 · registry result, not featured evidence insomnia 9.2% headache 8.2% constipation 6.1% NCT00535132 · Phase 4 · registry result, not featured evidence constipation 4.3% (placebo 3.4%) akathisia 2.1% (placebo 5.1%) headache 2.1% (placebo 1.7%) NCT01662310 · Phase 3 · registry result, not featured evidence akathisia 4.7% (placebo 5.1%) nausea 3.1% (placebo 0%) tremor 3.1% (placebo 0%) NCT01662310 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.3% somnolence 15.3% tremor 10.2% NCT00488319 · Phase 3 · registry result, not featured evidence weight increased 24.3% headache 18.9% somnolence 18.5% NCT00488319 · Phase 3 · registry result, not featured evidence somnolence 25.6% insomnia 17.9% anxiety 10.3% NCT00488319 · Phase 3 · registry result, not featured evidence akathisia 11.5% headache 10.6% somnolence 10.6% NCT01009047 · Phase 3 · registry result, not featured evidence akathisia 18.4% tremor 12.9% dystonia 8.7% NCT01541371 · Phase 3 · registry result, not featured evidence insomnia 15.6% headache 10.9% akathisia 9.4% NCT00473434 · Phase 3 · registry result, not featured evidence insomnia 23.1% tachycardia 8.5% headache 7.5% NCT00566631 · Phase 3 · registry result, not featured evidence insomnia 9.6% weight increased 9.6% headache 4.6% NCT00645099 · Phase 3 · registry result, not featured evidence insomnia 9.8% extrapyramidal disorder 6.6% headache 4.5% NCT01662648 · Phase 3 · registry result, not featured evidence insomnia 11.6% headache 4.1% nausea 3.9% NCT01662648 · Phase 3 · registry result, not featured evidence somnolence 20.8% (placebo 2%) akathisia 16.7% (placebo 0%) insomnia 12.5% (placebo 21.6%) NCT00518323 · Phase 3 · registry result, not featured evidence headache 9.3% (placebo 3.9%) insomnia 9.3% (placebo 21.6%) schizophrenia 9.3% (placebo 7.8%) NCT00518323 · Phase 3 · registry result, not featured evidence somnolence 14.6% (placebo 2%) akathisia 8.3% (placebo 0%) tremor 8.3% (placebo 0%) NCT00518323 · Phase 3 · registry result, not featured evidence insomnia 13.3% anemia 4.8% acute psychotic symptoms 1.6% NCT01606228 · Phase 3 · registry result, not featured evidence schizophrenia 16.4% (placebo 42.8%) insomnia 11.2% (placebo 10.1%) nasopharyngitis 10.4% (placebo 8%) NCT00396565 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 8 weeks versus 6 weeks.
- eAssessment timepoints differ: 26 weeks versus 24 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Asenapine
show 1 more result
show 1 more result
show 19 more results
show 15 more results
show 15 more results
show 17 more results
show 17 more results
show 17 more results
show 17 more results
+ 23 further endpoints in the CSV export.
Paliperidone (Invega)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 3 more results
show 2 more results
show 2 more results
show 25 more results
+ 58 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Asenapine's landscape · Paliperidone (Invega)'s landscape